1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,540 | 0,660 | 13:43 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | GENENTA SCIENCE SPA: Genenta, evolving into Saentra Forge, continues to evaluate strategic options for its original biotechnology platform derived from the research of Professor Luigi Naldini | 195 | GlobeNewswire (Europe) | MILAN, March 24, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge1, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian... ► Artikel lesen | |
| 13.03. | GENENTA SCIENCE SPA: Genenta, Evolving into Saentra Forge, Announces CEO's Appointment by the Italian Government to the Board of Guarantors of the Italian Academy at Columbia University | 425 | GlobeNewswire (Europe) | MILAN, March 13, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) transforming to Saentra Forge (Nasdaq: SAEN)1, a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 28.02. | Genenta Science SPA (GNTA) Shifting from Biotech to Defense Business | 3 | Insider Monkey | ||
| 27.02. | GENENTA SCIENCE SPA: Genenta Advances Transformation into Saentra Forge, Strengthens ATC Governance and Expands Strategic Industrial Consolidation Platform | 500 | GlobeNewswire (Europe) | MILAN, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA) in transformation to Saentra Forge (Nasdaq: SAEN), a strategic industrial consolidator focused on biotech, defense, aerospace... ► Artikel lesen | |
| 27.01. | Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments | 3 | Benzinga.com | ||
| 27.01. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.01. | GENENTA SCIENCE SPA: Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator | 351 | GlobeNewswire (Europe) | Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial... ► Artikel lesen | |
| 19.12.25 | GENENTA SCIENCE SPA: Genenta Science Provides Update on CEO Ownership | 304 | GlobeNewswire (Europe) | MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors... ► Artikel lesen | |
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | Aktie von Genenta Science schießt nach Update zu Glioblastom-Studie in die Höhe | 11 | Investing.com Deutsch | ||
| 24.11.25 | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 354 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen | |
| 28.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.10.25 | Aktie von Genenta Science stürzt nach 15-Millionen-Dollar-Kapitalerhöhung ab | 13 | Investing.com Deutsch | ||
| 27.10.25 | Genenta Science stock plunges after $15 million ADS offering | 2 | Investing.com | ||
| 27.10.25 | Genenta Science jumps on $15M direct offering | 3 | Seeking Alpha | ||
| 27.10.25 | Genenta Science raises $15 million in ADS offering at $3.50 per share | 4 | Investing.com | ||
| 27.10.25 | GENENTA SCIENCE SPA: Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Genenta Science Stock Jumps 85% On Strategic Collaboration With Anemocyte | 10 | RTTNews | ||
| 24.10.25 | Genenta Science stock soars on strategic LVV Plasmid DNA collaboration | 6 | Investing.com | ||
| 24.10.25 | Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech | 17 | Investing.com | ||
| 24.10.25 | GENENTA SCIENCE SPA: Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production | 1.637 | GlobeNewswire (Europe) | MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today... ► Artikel lesen |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOAFFINITY TECHNOLOGIES | 4,750 | 0,00 % | What's Going On With bioAffinity Stock Thursday? | ||
| APOGEE THERAPEUTICS | 79,16 | 0,00 % | Morning Market Movers: urban-gro, WeShop Holdings, QVC Group, Apogee Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:30 a.m. ET on Monday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| CG ONCOLOGY | 64,92 | 0,00 % | CG Oncology Inc.: CG Oncology Reports 2025 Year End Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC expected first half 2026CORE-008 Cohort CX Phase 2 first results of combination... ► Artikel lesen | |
| VERA THERAPEUTICS | 40,750 | 0,00 % | Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer | BRISBANE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments... ► Artikel lesen | |
| QIAGEN | 34,400 | +0,45 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| ERASCA | 14,310 | 0,00 % | Erasca (ERAS) Adds 13%; Soars 310% YTD | ||
| ARCELLX | 114,61 | 0,00 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| ADMA BIOLOGICS | 13,570 | 0,00 % | ADMA Biologics Announces $200 Mln Capital Return Plan | ||
| PRAXIS PRECISION MEDICINES | 293,87 | 0,00 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | Two new drug applications (NDA) for ulixacaltamide in essential tremor (ET) and for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs) have been submitted to the U.S.... ► Artikel lesen | |
| TYRA BIOSCIENCES | 36,500 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,400 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting | Bezuclastinib mean TSS reduction deepens to -32.0 points at 48 weeks of treatment with further improvement shown across all measured symptoms99% of patients achieve >50% reduction in serum tryptase... ► Artikel lesen | |
| BIONTECH | 76,00 | -1,43 % | Nach eigenem Bekunden konzentriert sich BioNTech bei der Suche nach einem neuen CEO vor allem auf die USA | Der kürzlich angekündigte Rücktritt der BioNTech Gründer Ugur Sahin und Özlem Türeci sorgte für einen Schock an der Börse und auch anderswo für Unsicherheit. Die Stadt Mainz scheint bereits darum zu... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 49,080 | +1,15 % | Citizens reiterates Structure Therapeutics stock rating on weight loss data | ||
| VALNEVA | 2,964 | -34,42 % | Valneva: Nettoverlust wegen Sondereffekt vervielfacht - Lyme-Daten entscheidend | Der Impfstoffhersteller Valneva hat im Geschäftsjahr 2025 einen Nettoverlust von 115,2 Millionen Euro ausgewiesen, nach einem Verlust von 12,2 Millionen Euro im Vorjahr. Der Vergleich ist jedoch durch... ► Artikel lesen | |
| ALUMIS | 23,370 | 0,00 % | Alumis Inc.: Alumis Reports Year End 2025 Financial Results and Highlights Recent Achievements | - Positive Phase 3 topline results demonstrating envudeucitinib's leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque psoriasis... ► Artikel lesen |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +0,020 (+3,85 %) liegt der Kurs bei 0,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.